Escalating immunotherapy of multiple sclerosis--new aspects and practical application

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Recent clinical studies offer new data on multiple sclerosis (MS) treatment, including clinically isolated syndromes, secondary progression, and immunomodulatory therapies.
• The Multiple Sclerosis Therapy Consensus Group (MSTCG) critically evaluated this data to optimize MS patient care.

Purpose of the Study:

• To provide recommendations for the application of immunoprophylactic therapies in multiple sclerosis.
• To critically evaluate recent clinical studies and meta-analyses concerning MS treatment options.

Main Methods:

• Critical evaluation of recent clinical studies and meta-analyses on multiple sclerosis treatments.
• Review of data on interferon beta efficacy, dosing, and treatment failure.
• Assessment of new diagnostic criteria and standardized clinical documentation.

Main Results:

• Initiation of MS treatment after the first relapse may be indicated with MRI evidence of subclinical dissemination.
• Interferon beta efficacy in secondary progressive MS is more likely with ongoing inflammatory activity.
• Data suggests a possible dose-effect relationship for recombinant beta-interferons, though studies require cautious interpretation.

Conclusions:

• The MSTCG recommends applying the McDonald et al. diagnostic criteria for considering immunoprophylactic treatment in MS.
• Standardized clinical documentation is proposed for systematic patient evaluation and retrospective analysis.
• Identifying secondary treatment failure and considering alternative options are crucial for long-term MS management.